comparemela.com

Card image cap


(1)
- ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice
- ICARE AD-US is one of three programs to generate post-approval data on ADUHELM, including the re-dosing Phase 3b EMBARK study and the planned confirmatory Phase 4 post-marketing requirement study
- Biogen aims to enroll at least 16 percent Latinx and Black/African American patients with Alzheimer's disease in the ICARE AD-US study as part of its commitment to increase participation from traditionally underrepresented communities
TOKYO, July 30, 2021 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo) today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer's disease called ICARE AD-US, at the Alzheimer's Association International Conference (AAIC), being held both virtually and in Denver, Colorado from July 26 - 30, 2021. ICARE AD-US, a prospective study of ADUHELMTM (aducanumab-avwa) 100 mg/mL solution for injection, is designed to collect real-world, long-term effectiveness and safety data on ADUHELM. The virtual oral session (#57522) was titled, "ICARE AD-US: design of a prospective, single-arm, multicenter, noninterventional real-world study of aducanumab in United States."

Related Keywords

Colorado , United States , Tokyo , Japan , Denver , Americans , American , Ivana Rubino , Harald Hampel , Eisai Co Ltd , Neurology Business Group , Alzheimer Association International Conference , Eisai Inc , Drug Administration , African American , Association International Conference , African Americans , White Americans , Global Head , Vice President , Chief Medical Officer , கொலராடோ , ஒன்றுபட்டது மாநிலங்களில் , டோக்கியோ , ஜப்பான் , டென்வர் , அமெரிக்கர்கள் , அமெரிக்கன் , ஹரால்ட் ஹ்யாஂபெல் , ேசை இணை லிமிடெட் , நரம்பியல் வணிக குழு , முதுமறதி சங்கம் சர்வதேச மாநாடு , ேசை இன்க் , சங்கம் சர்வதேச மாநாடு , வெள்ளை அமெரிக்கர்கள் , உலகளாவிய தலை , துணை ப்ரெஸிடெஂட் , தலைமை மருத்துவ அதிகாரி ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.